Cargando…

Real-world Efficacy Data on Anti-Angiogenic Drugs in Recurrent Small Cell Cervical Carcinoma: A Retrospective Study

OBJECTIVE: Small cell carcinoma of the cervix (SCCC) is rare but extremely aggressive and resistant to current therapies. We herein evaluate the efficacy of bevacizumab, apatinib, and anlotinib in recurrent/metastatic SCCC patients in a real-world setting. METHODS: Recurrent/metastatic SCCC patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qiu, Haifeng, Su, Ning, Yan, Shuping, Li, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996736/ https://www.ncbi.nlm.nih.gov/pubmed/36883253 http://dx.doi.org/10.1177/15330338231160393

Ejemplares similares

The efficacy of small molecule anti-angiogenic drugs in previously treated Thymic carcinoma
por: Guan, Yelan, et al.
Publicado: (2023)

Comparison of effects of anti-angiogenic agents in the zebrafish efficacy–toxicity model for translational anti-angiogenic drug discovery
por: Chimote, Geetanjali, et al.
Publicado: (2014)

Sales for anti-angiogenic drugs
por: Ribatti, Domenico
Publicado: (2017)

Revisiting anti-angiogenic therapy for recurrent glioblastoma
por: Peters, Katherine B.
Publicado: (2019)

An Oral Small Molecule VEGFR2 Inhibitor, Apatinib, in Patients with Recurrent or Refractory Cervical Cancer: A Real World Study
por: Li, Ning, et al.
Publicado: (2020)

Reactive resistance to anti-angiogenic drugs
por: Bousquet, Guilhem, et al.
Publicado: (2015)

Recurrent cervical cancer treated with palliative chemotherapy: real-world outcome
por: Mailankody, Sharada, et al.
Publicado: (2020)

Safety, Efficacy, and Drug Survival of Colchicine in Recurrent Aphthous Stomatitis in a Real-World Setting
por: Oh, Jongwook, et al.
Publicado: (2022)

Anti-Angiogenic Activity of Drugs in Multiple Myeloma
por: Saltarella, Ilaria, et al.
Publicado: (2023)

Quantitative proteomics analysis in small cell carcinoma of cervix reveals novel therapeutic targets
por: Qiu, Haifeng, et al.
Publicado: (2023)

The Anti-Angiogenic Effects of Anti-Human Immunodeficiency Virus Drugs
por: Barillari, Giovanni
Publicado: (2020)

Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study
por: Zheng, Zhuangzhuang, et al.
Publicado: (2022)

Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients
por: Qiu, Lupeng, et al.
Publicado: (2020)

Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation
por: Mas-Moruno, Carlos, et al.
Publicado: (2010)

Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study
por: Zhang, Kun, et al.
Publicado: (2020)

Real-World Efficacy of Bevacizumab in Patients With Recurrent Epithelial Ovarian Cancer
por: Hung, Jo-Ni, et al.
Publicado: (2022)

Anti-Angiogenic Effect of Triptolide in Rheumatoid Arthritis by Targeting Angiogenic Cascade
por: Kong, Xiangying, et al.
Publicado: (2013)

Angiogenic signaling pathways and anti-angiogenic therapy for cancer
por: Liu, Zhen-Ling, et al.
Publicado: (2023)

Anti-angiogenic drug scheduling optimisation with application to colorectal cancer
por: Sturrock, M., et al.
Publicado: (2018)

Anti-angiogenic drugs: direct anti-cancer agents with mitochondrial mechanisms of action
por: Quayle, Lewis A., et al.
Publicado: (2017)

Real-World Experience of Pembrolizumab Monotherapy in Patients with Recurrent or Persistent Cervical Cancer: A Korean Multi-Center Retrospective Study (KGOG1041)
por: Choi, Min Chul, et al.
Publicado: (2020)

Anti-angiogenic agents in the treatment of non-small cell lung cancer
por: Szyszka-Barth, Katarzyna, et al.
Publicado: (2014)

Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer
por: Tian, Wentao, et al.
Publicado: (2020)

Designing fisetin nanocrystals for enhanced in cellulo anti-angiogenic and anticancer efficacy()
por: Ma, Panpan, et al.
Publicado: (2022)

PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study
por: Chen, Shubin, et al.
Publicado: (2022)

729. Real World Efficacy of Bezlotoxumab for Prevention of Clostridioides Difficile Recurrence in Immunosuppressed Patients
por: Perreault, Sarah, et al.
Publicado: (2020)

MR spectroscopic imaging predicts early response to anti-angiogenic therapy in recurrent glioblastoma
por: Talati, Pratik, et al.
Publicado: (2021)

Endoglin (CD105) and proliferation index in recurrent glioblastoma treated with anti-angiogenic therapy
por: Bastos, António G. P., et al.
Publicado: (2022)

Anti-angiogenic and antitumor activities of Huaier aqueous extract
por: WANG, XIAOLONG, et al.
Publicado: (2012)

Anti-tumor and Anti-angiogenic Ergosterols from Ganoderma lucidum
por: Chen, Shaodan, et al.
Publicado: (2017)

Body Composition to Define Prognosis of Cancers Treated by Anti-Angiogenic Drugs
por: Decazes, Pierre, et al.
Publicado: (2023)

Nephrotoxicity of Anti-Angiogenic Therapies
por: Van Wynsberghe, Margaux, et al.
Publicado: (2021)

Anti-Angiogenic Drugs Inhibit Interstitial Lung Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer
por: Wang, Yanning, et al.
Publicado: (2022)

Serum Angiogenic and Anti-angiogenic Markers in Pregnant Women with Placenta Percreta
por: Uyanıkoğlu, Hacer, et al.
Publicado: (2018)

Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer
por: Hong, Min Hee, et al.
Publicado: (2019)

Newly developed anti-angiogenic therapy in non-small cell lung cancer
por: Qu, Jingjing, et al.
Publicado: (2017)

High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study
por: Nie, Caiyun, et al.
Publicado: (2023)

Deciphering Combinations of PI3K/AKT/mTOR Pathway Drugs Augmenting Anti-Angiogenic Efficacy In Vivo
por: Sasore, Temitope, et al.
Publicado: (2014)

Clinical efficacy and safety of maintenance therapy for advanced non-small cell lung cancer: a retrospective real-world study
por: Xu, Xiangwei, et al.
Publicado: (2021)

A retrospective real‐world experience of immunotherapy in patients with extensive stage small‐cell lung cancer
por: Qiu, Guihuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cp4naadv6g6nt68i4mssa3c5ol